Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Short Interest Down 42.5% in July

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) was the target of a significant decline in short interest in July. As of July 15th, there was short interest totalling 10,300 shares, a decline of 42.5% from the June 30th total of 17,900 shares. Currently, 0.8% of the company’s shares are sold short. Based on an average daily trading volume, of 111,500 shares, the days-to-cover ratio is currently 0.1 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Pieris Pharmaceuticals stock. Summit Trail Advisors LLC acquired a new position in shares of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 140,000 shares of the biotechnology company’s stock, valued at approximately $26,000. Summit Trail Advisors LLC owned approximately 0.14% of Pieris Pharmaceuticals as of its most recent filing with the SEC. Hedge funds and other institutional investors own 40.11% of the company’s stock.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on Pieris Pharmaceuticals in a research note on Friday, July 12th. They set a “hold” rating for the company.

Pieris Pharmaceuticals Trading Down 1.7 %

PIRS traded down $0.30 on Friday, hitting $17.01. 86,103 shares of the company were exchanged, compared to its average volume of 57,636. Pieris Pharmaceuticals has a twelve month low of $6.20 and a twelve month high of $41.78. The company has a market cap of $22.45 million, a price-to-earnings ratio of -1.42 and a beta of 0.68. The firm has a 50-day moving average price of $9.44 and a two-hundred day moving average price of $11.99.

Pieris Pharmaceuticals (NASDAQ:PIRS) last released its earnings results on Wednesday, May 15th. The biotechnology company reported ($3.95) EPS for the quarter. Pieris Pharmaceuticals had a negative return on equity of 57.57% and a negative net margin of 39.71%. The company had revenue of $0.05 million for the quarter.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.